Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-25-000153
Filing Date
2025-08-07
Accepted
2025-08-07 17:34:32
Documents
1
Period of Report
2025-08-05

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1754602468.html 4  
1 FORM 4 wk-form4_1754602468.xml 4 7397
  Complete submission text file 0001714899-25-000153.txt   8888
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address
Ho Carole (Reporting) CIK: 0001724605 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 251195529